LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA ® in Germany, the second European market where the product is now available.
Since May 1st, 2013, JETREA ® is listed in the "Lauer-Taxe" (Große Deutsche Spezialitätentaxe) with an ex-factory price of € 3,078.
In mid-March 2013, JETREA ® was approved by the European Commission (EC)for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.Today's kick off in Germany's private and public market, follows Alcon's first European launch of JETREA ® which took place in the UK last month. Alcon, a division of Novartis, acquired the rights to commercialize JETREA ® outside the United States in March 2012. Under the terms of this deal ThromboGenics has already received €165 million in upfront and milestone payments, including €90 million following EMA approval of JETREA ® and first injection (UK) in patients. The company could receive a further €210 million in milestones plus significant royalties on Alcon's sales of JETREA ®. ThromboGenics launched JETREA ® in the US in mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA). Dr Patrik De Haes, CEO of ThromboGenics, says: " We are very excited to see that JETREA ® has quickly become available as a privately and publicly reimbursed drug in Germany . Today ' s launch by Alcon in Germany is a key step in making this exciting new pharmacological treatment for VMT available to more patients in Europe . " JETREA ® contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with vitreomacular traction (VMT). VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognising faces.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts